Background: Fluoroquinolones are among the most widely prescribed antibiotics. However,concerns about increasing resistant microorganisms and the risk of dysglycemia associated withthe use of these agents have emerged.Objective: The primary objective of the study was to evaluate the appropriate use of commonlyprescribed fluoroquinolones, including appropriate indication, dose, dose adjustment inrenal impairment, and duration of treatment. The secondary objective was to investigate thedysglycemic effect of fluoroquinolone use (hypoglycemia and/or hyperglycemia) in diabeticand nondiabetic patients.Methods: A prospective observational study at a teaching hospital in Lebanon was conductedover a 6-month period. A total of 118 patients receiving broad-spectrum fluoroquinolones(levofloxacin, ciprofloxacin, and moxifloxacin) were identified. Patients were mainly recruitedfrom internal medicine floors and intensive care units.Results: The final percentage for the appropriate indication, dose, and duration of fluoroquinolonetherapy was 93.2%, 74.6%, and 57.6%, respectively. A total of 57.1% of the patientsdid not receive the appropriate dose adjustment according to their level of renal impairment. Inaddition, dysglycemia occurred in both diabetic and nondiabetic patients. Dysglycemia was morefrequently encountered with ciprofloxacin (50.0%), followed by levofloxacin (42.4%) and moxifloxacin(7.6%). Hyperglycemia was more common than hypoglycemia in all groups. The highestincidence of hyperglycemia occurred with levofloxacin (70.0%), followed by ciprofloxacin(39.0%) and moxifloxacin (33.3%). In contrast, hypoglycemia did not occur in the ciprofloxacingroup, but it was more common with moxifloxacin (11.1%) and levofloxacin (6.0%).Conclusion: The major clinical interventions for the future will adjust the dose and durationof therapy with commonly prescribed fluoroquinolones. The incidence of hypoglycemia wasless common than hyperglycemia.
展开▼
